Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, under the FDA's Generally Recognized as Safe (GRAS) guidelines [1] Group 1: Product Information - Glyceryl Phosphoryl Choline is a naturally occurring choline compound in the human body and a key component of brain cell membranes [1] - It is recognized as a highly bioavailable source of choline with core benefits that have been validated through extensive research [1] Group 2: Core Benefits - The product is known to enhance cognitive function and support normal brain operation to maintain brain health [1] - It aids in improving athletic performance and post-exercise recovery [1] - It provides neuroprotective effects, ensuring the health of the nervous system [1]

Core Viewpoint - The company has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, through rigorous scientific evaluation in accordance with FDA's GRAS guidelines [1] Group 1: Product Information - Glyceryl Phosphoryl Choline is a naturally occurring choline compound in the human body and a key component of brain cell membranes [1] - It serves as a highly bioavailable source of choline, with core benefits including enhancement of cognitive function, support for normal brain operation to maintain brain health, improvement of athletic performance and post-exercise recovery, and neuroprotective effects for the health of the nervous system [1]

Core Viewpoint - Toxin Pharmaceutical's subsidiary, Jingquan Biotechnology, has successfully obtained Self-GRAS status for its product, Glyceryl Phosphoryl Choline, from the FDA, which is a significant milestone for market entry in the U.S. and other regions recognizing FDA standards [1] Group 1 - Toxin Pharmaceutical's subsidiary, Jingquan Biotechnology, completed a rigorous scientific evaluation for Glyceryl Phosphoryl Choline [1] - The Self-GRAS certification is one of the highest levels of recognition established by the FDA for the safety of food additives and dietary ingredients [1] - The successful certification provides a critical "passport" for the product to enter the U.S. market and other international markets that recognize FDA standards [1]

Core Viewpoint - The company, Tuoxin Pharmaceutical, announced that its subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has successfully obtained Self-GRAS status for its product, Glycyrrhizin Choline, from the FDA, which is a significant milestone for entering the U.S. and other international markets that recognize FDA standards [1] Group 1: Regulatory Approval - The product Glycyrrhizin Choline has passed the FDA's Generally Recognized as Safe (GRAS) evaluation, securing a key "passport" for market entry [1] - This certification is expected to facilitate the expansion into high-end food, dietary supplements, and special medical food markets globally [1] Group 2: Market Impact - The approval is anticipated to optimize the company's product structure and enhance overall profitability [1] - However, future market promotion may face challenges from policy adjustments and intensified market competition, leading to uncertainty regarding the sales contribution to the company's overall operations [1]

中文名称：甘磷酸胆碱 英文名称：L-α-Glycerylphosphorylcholine（简称"L-α-GPC"） 证券代码：301089 证券简称：拓新药业 公告编号：2025-050 拓新药业集团股份有限公司 关于全资子公司产品通过美国Self-GRAS认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）全资子公司新乡精泉生物 技术有限公司（以下简称"精泉生物"）的产品甘磷酸胆碱，已依据美国食品药 品监督管理局（FDA）的"一般认为安全"（GRAS）准则完成严格科学评价，成 功获得 Self-GRAS 身份。现将相关情况公告如下： 一、产品基本情况 同时，认证为精泉生物开拓全球高端食品、膳食补充剂及特医食品市场奠定坚实 基础，有望进一步优化公司产品结构，提升整体盈利能力。 三、风险提示 本产品后续市场推广可能面临政策调整、市场竞争加剧等外部因素影响，其 销售业绩对公司整体经营的具体贡献存在不确定性，敬请广大投资者保持理性投 资，注意投资风险。 特此公告。 拓新药业集团股份有限公司 董事会 产品特性与应 ...

证券日报网讯拓新药业（301089）10月14日在互动平台回答投资者提问时表示，截至2025年10月10日， 公司股东户数17815户。 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-049 类型：有限责任公司（非自然人投资或控股的法人独资） 注册资本：5000万元人民币 法定代表人：邢善涛 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、本次变更情况 拓新药业集团股份有限公司（以下简称"公司"）子公司拓新药业（三亚） 有限公司近期变更了公司名称及住所。于近日完成工商变更登记手续，并取得了 海南省市场监督管理局核发的《营业执照》。现将具体情况公告如下： 二、新取得营业执照基本信息 名称：拓新药业（海南）有限公司 统一社会信用代码：91460107MACDDQNA0R 拓新药业集团股份有限公司 关于全资子公司变更名称、注册地址并完成工商变更登记的 公告 成立日期：2023年03月28日 住所：海南省三亚市崖州区崖州湾科技城招商三亚深海装备产业园二期4栋 经营范围：许可项目：技术进出口；货物进出口；药品生产；药品委托生产； 食品添加剂生产；药品零售；药品批发（许可经营项目凭许可证件经营） 一般经营项目： 医学研究和试验发展（除人体干细胞、基因诊断与治疗技术开发和应用）； 工程 ...

Group 1 - The core viewpoint of the news is that拓新药业 experienced a decline in stock price and significant changes in financing activities on October 9, with a net financing outflow of 374.02 million yuan [1] - On October 9, the stock price of拓新药业 fell by 1.02%, with a trading volume of 73.72 million yuan [1] - As of October 9, the total balance of margin trading for拓新药业 was 155 million yuan, which accounts for 3.93% of its market capitalization [1] Group 2 - As of September 19, the number of shareholders of拓新药业 was 16,500, a decrease of 26.77% from the previous period [2] - The average number of circulating shares per shareholder increased by 36.55% to 5,527 shares [2] - For the first half of 2025,拓新药业 reported a revenue of 182 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to shareholders of -18.28 million yuan, a decrease of 927.39% [2] Group 3 - The main business of拓新药业 includes the research, production, and sales of chemical synthesis, biological fermentation nucleoside (acid) raw materials, and pharmaceutical intermediates [1] - The revenue composition of拓新药业 is 62.74% from pharmaceutical intermediates, 37.03% from raw materials, and 0.23% from other sources [1] - Since its A-share listing,拓新药业 has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2]

证券日报网讯拓新药业（301089）9月26日在互动平台回答投资者提问时表示，截至2025年9月19日，公 司股东户数16458户。 ...

Group 1 - On September 25, Toxin Pharmaceutical experienced a decline of 1.54% with a trading volume of 60.37 million yuan [1] - The financing data on the same day showed a financing purchase amount of 3.99 million yuan and a financing repayment of 7.89 million yuan, resulting in a net financing outflow of 3.89 million yuan [1] - As of September 25, the total balance of margin trading for Toxin Pharmaceutical was 157 million yuan, with a financing balance of 156 million yuan, accounting for 4.02% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of July 31, the number of shareholders for Toxin Pharmaceutical increased by 7.72% to 22,500, while the average circulating shares per person decreased by 7.16% to 4,048 shares [2] - For the first half of 2025, Toxin Pharmaceutical reported an operating income of 182 million yuan, a year-on-year decrease of 16.85%, and a net profit attributable to the parent company of -18.28 million yuan, a significant year-on-year decrease of 927.39% [2] - Since its A-share listing, Toxin Pharmaceutical has distributed a total of 94.64 million yuan in dividends, with 82.04 million yuan distributed over the past three years [2]